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Summary The bladders of anaesthetised mice were illuminated with red laser light (630 nm) at intervals of I
day to 4 weeks after i.p. administration of Photofrin. Light was delivered intravesically by inserting a fibre
optic, with a diffusing bulb tip, into the centre of fluid filled bladders. A single light dose of 11.3 J cm-2
applied 1 day after 10 mg kg-' Photofrin caused a severe acute response, with increased urination frequency
(five to seven times control) and haematuria. Recovery was good, however, and by 10 weeks only a mild
(approximately two-fold) increase in frequency remained. There was no reduction in the amount of acute
bladder damage or in the rate of healing when the interval between Photofrin and light was increased from 1
to 7 days but a 2 to 3 week interval lead to a significant reduction in damage. For an interval of 4 weeks there
was only a mild (less than two-fold) increase in urination frequency during the first week. A drug dose of
2.5 mg kg-I given I day before illumination caused transient haematuria but no increase in urination
frequency. Doses of 5, 7.5 or 10 mg kg-' all caused photosensitisation and the amount of bladder damage was
drug dose dependent. The bladder seems to be well able to recover from severe acute damage induced by PDT.
Occasional incidences of pyelonephritis were seen, however, suggesting that urinary tract infection during the
acute period may lead to permanent renal damage.
There is increasing interest in the use of PDT for the treat-
ment of non-invasive bladder cancer, especially carcinoma in
situ (CIS). Early clinical trials used illumination of individual
bladder tumours after systemic administration of photosen-
sitiser (Benson, 1985; Hisazumi et al., 1983). Due to the
multifocal nature of bladder cancer, it is probably better to
treat the entire mucosa with uniform illumination, particular-
ly for CIS (integral PDT). Individual papillary lesions may be
given additional focal PDT (Prout et al., 1987). Preliminary
results from clinical studies using integral PDT for superficial
bladder cancer are promising (Naito et al., 1901; Prout et al.,
1987; Nseyo et al., 1987; Shumaker & Hetzel, 1987; Harty et
al., 1989; D'Hallewin et al., 1992; Jocham, 1987) but follow
up of the patients is still fairly short (less than 1 year in many
cases). Many aspects of PDT, such as the optimal timing of
light delivery and optimal light and sensitiser doses still have
to be defined to achieve effective tumour response without
loss of bladder function. Nearly all clinical studies in which
the whole bladder is treated with PDT report a high inci-
dence of bladder irritability, increased urination frequency
and haematuria during the first few weeks after treatment
(Naito et al., 1991; Prout et al., 1987; Nseyo et al., 1987;
Harty et al., 1989; D'Hallewin et al., 1992; Benson, 1985;
Hisazumi et al., 1983; Jocham, 1987). This may be an
unavoidable consequence of treatment, since successful ther-
apy involves urothelial sloughing and exposure of the sub-
mucosa as the malignant (and premalignant) areas are shed.
Both experiment and clinical studies, however, indicate a
remarkable degree of recovery from the acute damage (Naito
et al., 1991; Prout et al., 1987; Nseyo et al., 1987; Sindelar et
al., 1991; Stewart et al., 1992; Pope & Bown, 1991), within
certain tolerance limits. The consequence of exceeding these
tolerance limits may be a permanently shrunken bladder
requiring cystectomy, as evidenced by several clinical studies
in which the non-scattered light dose to the whole bladder
exceeded 15 to 20 Jcm-2 (D'Hallewin et al., 1992; Harty et
al., 1989).
The biological effect of PDT depends on the concentration
of photosensitiser in the tissue and on the light dose applied.
A major systemic side effect of haematoporphyrin derivative
sensitisers, such as Photofrin, is a generalised skin photosen-
sitivity which lasts for 4 to 8 weeks. It would therefore be
advantageous to reduce the drug doses used to a minimum
required to produce an acute epithelial response in the blad-
der. It would also be of interest to know how long photosen-
sitisation persists after injecting the drug. This would aid
treatment planning if unavoidable delays in the illumination
procedure occur, or if retreatment is indicated. The purpose
of this study was therefore to determine the influence of
sensitiser dose (Photofrin) and time of administration on the
extent of damage and recovery in normal bladder, using a
mouse model.
Methods
Photodynamic therapy
Female mice of the strain C3H/Hen Af-nu+ (weighing 25 to
30 g, at 15 to 20 weeks) were used. Photofrin (supplied free
of charge by Lederle, Cyanamid, The Netherlands) was given
intraperitoneally at doses of 2.5, 5.0, 7.5 or 10 mg kg- '. The
drug was supplied as a freeze dried preparation which was
dissolved in 5% dextrose to a concentration of 2.0 mg ml-'.
The stock solution was divided into aliquots and stored in
the dark at - 20°C until required. Since the experiments
described in this manuscript were carried out over a period
of almost 2 years, more than one batch of Photofrin was
used. A 'standard' treatment group of 10 mg kg-', 24 h
before illumination was therefore included with each experi-
ment. All mice were kept in subdued lighting for 1 week after
injection of the photosensitiser.
The bladders of mice were illuminated as previously des-
cribed (Stewart et al., 1992), at intervals of 1 to 26 days after
l0mgkg-' Photofrin, or at 1 day after 2.5 to l0mgkg'-.
For the illuminations mice were anaesthetised (60 mg kg'-
sodium pentobarbitone i.p.) and the bladders emptied of
urine with a catheter (vI90 Venflon 22G/0.8 mm). The blad-
der was then filled with 0.2 ml of saline via a catheter
inserted to a distance of 15 mm from the urethral opening.
The light delivery fibre was passed through a specially
adapted syringe and catheter and was positioned so that the
fibre tip was at the end of the catheter in the centre of the
fluid filled bladder. The fibre was plastic coated quartz (exter-
nal diameter 125ptm) with an isotropic diffusing bulb tip
(500pm). For illumination of the bladders, the anaesthetised
mice were inverted with the catheter and fibre in position.
Inversion served two purposes: (a) the intestines dropped
downwards out of the illumination field, (b) the vertical
alignment of the bladder increased the probability of cor-
Correspondence: F.A. Stewart.
Received 12 January 1993; and in revised form 10 May 1993.
Br. J. Cancer (1993), 68, 673-677 '." Macmillan Press Ltd., 1993674 F.A. STEWARTS & Y. OUSSOREN
rectly positioning the fibre in the centre of the bladder. The
light delivery fibre was coupled to a 12 W argon laser
(Spectra-Physics model 171), which powered a dye laser
(Spectra-Physics model 375) tuned to 630 ± 3 nm. A power
setting of 75 mW was used and the output from the fibre tip
was checked (in air) before and after each treatment with an
integrating light sphere. The illumination time was kept con-
stant at 3'20", giving an incident, non-scattered light dose of
15 J per bladder. Measurements of the bladder size after
filling with 0.2 ml saline (in a separate group of 18 mice)
indicated a mean surface area of 134 ± 25 mm2 ( ± 1 s.d.),
calculated from the geometric mean diamater of the bladders
measured in three orthoganol directions, assuming a spher-
ical shape. This is less than would be expected for an instilla-
tion volume of 0.2 ml, but small quantities of liquid often
leaked during filling. Using the calculated surface area of
representative bladders the 15 J per bladder is equivalent to a
non-scattered dose of 11.3 J cm-2. In fact, the bladders were
ellipsoidal (typically 8 x 6 x 6 mm, ± 0.5 mm for each di-
mension), which will increase the surface area by 23%
relative to a sphere. The quoted dose of 11.3 J cm-2 is
therefore an upper estimate (Marijnissen et al., 1993).
Assaysforfunctional bladder damage
Mice were tested for urination frequency and the presence of
haematuria at weekly intervals for the first month, monthly
until 6 months and again at 9 and 12 months. Urination
frequency tests were carried out over a 24h period during
which the mice were placed in individual cages with wire bar
floors (with free access to food and water). Absorbent paper
was drawn beneath the cages and at the end of the test
period the number of discrete urination events was counted
as previously described (Stewart et al., 1978; Edrees et al.,
1988). The volume of urine produced by each mouse was also
estimated by comparing the area of each urine spot with a
calibration curve for known volumes of urine. Urination
frequency was expressed as the number of urination events
per 24 h and then corrected for the volume of urine pro-
duced. This parameter is defined as the frequency index
(spots per ml). The urine volumes produced by treated mice
were generally within the control range (1.6 to 3.2 ml), how-
ever, during the first 4 weeks after PDT about 40% of the
mice had a significant reduction in urine volume. This
reflected a temporary deterioration in the condition of the
mice, with dehydration and 10 to 20% weight loss. If the
urine production in a 24 h test period was less than 0.45 ml,
no estimate of FI was made at that testing time.
The presence of haematuria was determined using standard
Bili labstix. These tests were always carried out between
09.00 h- 11.00 h, by dipping the test strips in fresh urine
samples. Results were scored as positive or negative only,
with no attempt to define the degree of haematuria.
Histology
Separate groups of animals were sacrificed at intervals of 1
day, 1, 4, 10 and 15 weeks after PDT (5 or 10mgkg-'
Photofrin, given 1 day before illumination) and the bladders
examined histologically (two or three bladders per time
point). In addition, all bladders and kidneys were taken for
histological examination at the end of the 1 year follow up
period (six to ten specimens per group). Bladders were
excised immediately after sacrifice (by cervical dislocation)
after instillation with 100-200 tLI fixative (ethanol:acetic acid:
formaldehyde:saline; 40:5:10:45 v/v). After 24 h in fixative
the bladders were transferred to 70% alcohol until they were
prepared for histology. The fixed bladders were bisected lon-
gitudinally, embedded in paraffin wax and cut at 5 ytm (lon-
gitudinal sections were made from the central part of the
bladder). Sections were routinely stained with haematoxylin
and eosin and examined without knowledge of the treatment.
Selected speciments were also stained with AZAN, to
differentiate between fibrin and collagen deposition in the
submucosa.
Results
The mean Frequency Index (FI) for control animals over the
52 week testing period was 5.1 spots ml-' ( ± 2.2, 1 s.d.), i.e.
a mean of 2.7 ml urine excreted as 13.8 spots during the 24 h
test period. Light alone (11.3 Jcm-2 non-scattered dose) or
Photofrin alone (1Omg kg-' i.p.) did not alter the frequency
of urination.
A total of four separate experiments contributed to the
results described here and for each experiment a group of six
to nine mice were treated with a standard drug dose of
10mgkg-' at 24h before 11.3 Jcm2. This dosing schedule
produced a large increase in Fl in all mice during the first
week after treatment (at least a five-fold increase in FI
compared with controls). There was a fairly rapid recovery
over the first 4 weeks, followed by a more gradual return
towards control levels (Figure 1). At 52 weeks the mean FI
of all the treated mice from the four experiments was 9.5
spots ml1' (significantly above control levels (P<.01)) and
30% of these animals still had a two-fold increase in Fl. The
frequency response of mice treated in the four separate
experiments was generally very similar, although recovery
from 18 to 38 weeks was slightly slower in experiments 1 and
4 (experiment 1 also gave the largest increase in FT during
the first 2 weeks). Since the difference in response between
the experiments was small, all the mice treated with 1Omg
kg-' Photofrin at 24 h before a non-scattered light dose of
11.3 J cm-2 were analysed together to produce a single time
response curve for comparison with other treatment sched-
ules (Figures 2 to 4).
Influence ofPhotofrin dose
Illumination at day 1 after 5 or 7.5 mg kg-' Photofrin
resulted in less acute damage (P<0.01 at 1 week) and a
more rapid return to control levels (P< .05 at 10 to 26
weeks) than 10mg kg-'. A dose of 2.5 mg kg-' did not cause
any significant increase in FI at any testing time (Figure 2).
The mean FT was not significantly increased (P>.05) above
control from 14 weeks after PDT with 5 or 7.5 mg kg-'
Photofrin (Figure 2) but a few of these animals (< 20%) had
a two-fold increase in Fl until 36 weeks.
Almost all mice (>80%) which were illuminated 1 to 7
days after 1Omg kg- Photofrin developed haematuria dur-
ing the first week. This decreased over a period of 4 weeks
and beyond 10 weeks there was only mild, incidental (<
10%) haematuria (occasionally haematuria was also seen in
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Figure 1 Time changes in urination frequency index for groups
of mice treated with 10 mg kg-' Photofrin, 24 h before bladder
illumination with an incident, non-scattered light dose of 11.3 J
cm-2. Each experiments shows the mean (± 1 s.e.m. on represen-
tative groups) Fl for a group of six to nine mice. The shaded area
indicates the mean FT of untreated control animals over the
entire testing period (± I s.d.).PDT IN MOUSE BLADDER 675
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Figure 2 Time changes in mean FT for mice treated with 2.5 to
10 mg kg-' Photofrin at 24 h before 11.3 J cm-2. Each group
contains a mimimum of seven mice and the 10 mgkg-' dose
group consists of a total of 33 mice from four separate experi-
ments (see Figure 1). Errors are ± I s.e.m. The shaded area in-
dicates mean FT of controls.
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Figure 3 Time changes in mean FT after PDT with 10 mg kg-'
Photofrin given 6 h to 7 days before illumination with 11.3 J
cm-2. The response of untreated controls or animals treated with
light alone is also shown. Errors (on representative treatment
groups) are ± I s.e.m. The I day interval dose group consists of
a total of 33 mice from four separate experiments, other groups
contain a minimum of seven mice.
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the older untreated or light alone mice). Drug doses of 2.5 to
7.5 mg kg-' with a non-scattered light dose of 11.3 Jcm-2
caused a 40-60% incidence of haematuria, which generally
persisted for a maximum of 4 weeks.
Influence oftime interval between Photofrin and illumination
A drug dose of 10 mg kg-' given at intervals of 1, 2, 3, 5 or 7
days before illumination gave the same amount of bladder
damage. There was no significant difference between these
groups in terms of the acute response (increased urination
frequency and haematuria), or the rate of recovery. Figure 3
illustrates results for the 1 and 7 day intervals, expressed as a
mean FT. It was predicted that Photofrin given only 6 h
before illumination might result in more bladder damage, but
this was not the case. The acute FT response was the same as
for intervals of 1 to 7 days and the rate of recovery was even
slightly faster (not significant).
When the interval between Photofrin administration and
illumination was increased to 2 to 4 weeks there was
significantly less acute damage (FI) and rapid recovery to
control levels within 3 to 4 weeks (Figure 4).
Histology
At 1 day to 1 week after PDT (S or 10 mg kg-' Photofrin, 1
day prior to illumination with a non-scattered light dose of
11.3 J cm-2) all bladders exhibited moderate to severe acute
damage, consisting of vessel dilatation, oedema, polymor-
phonuclear inflammatory infiltrates and fibrin extravasation.
These changes were predominantly seen in the submucosa
and muscle layers were generally unaffected. Multifocal epi-
thelial sloughing was sometimes present as early as 1 day
after treatment but was always seen at 1 week, often with
complete mucosal denudation. In some cases, bacterial col-
onies were identified within the cellular debris and fibrin
covering the bladder wall. By 4 weeks the mucosa had re-
epithelialised; focal submucosal fibrosis and oedema, with
areas of inflammatory infiltrate, remained. Many bladder
specimens from animals sacrificed in the first 10 weeks were
surrounded by hard, often necrotic, fat which adhered to the
outer surface of the bladder. In most instances the his-
tological features of the bladder had returned to near normal
after 10 to 15 weeks, mild submucosal fibrosis being the only
notable abnormality. However, approximately 10% of the
specimens examined at 10 to 15 weeks, or at 1 year (total of
73 PDT treated bladders) had a more severe damage, consis-
ting of fibrotic shrinkage of the bladder and, sometimes,
focal muscle necrosis with calcification. These changes were
entirely consistent with our previously published observations
(Stewart et al., 1992).
Kidneys were also examined histologically and a total of
five out of 75) animals had evidence of marked chronic
pyelonephritis, with interstitial inflammatory infiltrates assoc-
iated with atropy of the parenchyma at 1 year after treatment
(Figure Sa). In one case this was associated with a very
severe inflammatory bladder reaction but the bladders of the
other 4 mice with renal damage appeared normal (Figure
Sb). In addition, several kidneys of mice sacrificed during the
first 10 weeks exhibited mild tubular widening consistent with
congestion and an impeded urinary outflow (Figure Sc). The
bladders of these animals always showed an acute inflam-
matory and/or epithelial denudation response (Figure Sd).
T - Discussion
Most patients treated with whole bladder PDT develop mild
10 20 30 40 50 60 to moderately severe acute reactions with haematuria, dys-
uria and urination frequency lasting for up to 3 months Time after treatment (weeks) (Benson, 1985; Nseyo et al., 1987; Naito et al., 1991; Prout et
4 Time changes in mean FI after PDT with 10 mg kg-' al., 1987; D'Hallewin et al., 1992). This acute reaction is, to
ofrin at 2 to 4 weeks before illumination with 11.3 Jcm-2. some extent, an inevitable consequence of successful whole
nean response of animals illuminated at 24 h after 10 mg bladder PDT, since the initial inflammatory response and
Photofrin is also shown. shedding of the urothelium, along with neoplastic and pre-
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Figure 5 Histological sections of kidneys (left) and bladders (right) from the same mice. Five ,im sections were stained with
haematoxalin and eosin, original magnification x 100. a,b: 1 year after PDT (10 mgkg-' Photofrin/11.3 Jcm-2). Chronic
pyelonephritis with interstitial inflammatory infiltrates (arrow), atrophy (A) of the renal parenchyma and glomerular degeneration
(G). The bladder from this animal (b) was normal, with an intact epithelium (E) and no muscle damage (M). c,d: 1 day after PDT
(10 mg kg-' Photofrin/l 1.3 J cm-2). Renal cortex contains many abnormally wide tubules (W). The bladder from this animal (d)
exhibited a marked inflammatory response with extensive submucosal oedema (0), fibrin deposits and polymorphonuclear
inflammatory cells in the submucosa (not visible). The epithelium was sloughing and becoming detached from the submucosa in
many places (E). Necrotic fat adhered to the outer wall of the bladder (N). e,f: Control specimens of kidney and bladder from an
untreated mouse (same magnification as a to d).
neoplastic lesions, are probably required for effective tumour
control. Permanent reductions in bladder capacity neces-
sitating cystectomy are rare but can occur, particularly if
PDT is given within 4 weeks of TUR, or if high total light
doses are given (Harty et al., 1989; D'Hallewin et al., 1992).
The biological effect of PDT is determined by the energy
absorbed by the photosensitiser. For a constant light dose,
effect is determined by the tissue drug concentration, which
depends on both administered dose and the time interval
allowed before illumination. The rationale for delaying illum-
ination for 48-72 h after administration of haematoporphy-
rin derivative sensitisers is that these compounds are cleared
less rapidly from tumours than normal tissues and that a
better therapeutic ratio is obtained by delaying illumination.
Recent experiments of Baumgartner et al. (1992), for exam-
ple, demonstrated similar levels of Photofrin in chemically
induced rat bladder tumours and the surrounding normal
bladder at 24 h after injection, but a 2 to 5-fold higher drug
level in the tumour at 2 to 10 days. Detectable levels of the
fluorescent component of Photofrin were, however, present in
the normal bladder for up to 10 days. Drug uptake and
distribution studies in mice have also demonstrated a slow
clearance of these sensitisers from other normal tissues (Peng
et al., 1991; Bellnier et al., 1989), with detectable drug levels
in muscle, skin, heart, lung, spleen, kidney and liver at 75
days after injection of 5 mg kg-' Photofrin (Bellnier et al.,
1989). Several studies have also demonstrated longer elimina-
tion times for Photofrin (plasma and tissue) after i.p. admin-
istration than after i.v. administration, although absolute
drug concentrations were higher in some organs (liver and
kidney) after i.v. administration (Bellnier et al., 1989; Peng et
al., 1991). Photofrin levels in the bladder were not measured
in these studies. We have never examined the bladder res-
ponse to PDT after i.v. administration of Photofrin and it is
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possible that route of injection may affect the extent of
damage. Further studies will be required to clarify this issue.
The present studies demonstrate that there was no decrease
in the extent of photosensitisation in normal mouse bladder
for light applied at 1 to 7 days after 10mgkg1 Photofrin.
This would have the practical consequence that any unplan-
ned delay in illumination would not be expected to reduce
the efficacy of treatment, provided that illumination occurred
within 1 week. It may also be possible to re-illuminate the
bladder at any time during the first week, without the need
for additional photosensitiser, if repeated therapy was judged
to be necessary. This would, however, only be true if
photobleaching (from the first illumination) had not reduced
sensitiser levels in the tumour to below a therapeutic level.
Interestingly, there was no evidence for increased bladder
damage when the interval between drug an illumination was
reduced to 6 h. It is not known whether i.v. administration of
Photofrin would have lead to an increased response at 6 h.
Doses of 5 to 10 mg kg-' Photofrin at 1 day before
illumination all caused significant increases in urination fre-
quency and haematuria during the first 4 weeks. Histology
confirmed that the functional damage induced by 5 or
10mg kg-' was associated with a moderate to severe
inflammatory response (in the mucosal and submucosal
layers), with submucosal oedema and epithelial sloughing in
all cases. Re-epithelialisation appeared to be almost complete
within 4 weeks. The kidneys of PDT treated animals were
also routinely taken for histology after sacrifice at 1 year and
an occasional (< 10%) incidence of pyelonephritis was seen.
In one case this was associated with very severe bladder
damage with bacterial infection and ascending urinary tract
infection may have been the cause of the renal damage.
There were, however, a few mice with severe renal damage
where the bladders appeared normal. In these mice, transient
ureteral sclerosis, probably caused by inflammatory changes
during the acute reaction, may have impeded the normal flow
of urine and contributed to an ascending urinary tract infec-
tion. It is unlikely that the renal damage observed in these
studies occurred as a direct result of phototoxicity in the
kidney, since the light dose (measured in situ) at the position
of the kidney was less than 10% of the bladder dose. It is of
interest that hydronephrosis has also occasionally been see in
in patients treated with PDT of the bladder (Harty et al.,
1989).
An optimal photodynamic treatment for whole bladder
could be defined as a combination of light and drug doses
which gives a moderately severe acute response, with
inflammation and epithelial sloughing, and complete healing
over a period of a few weeks. Our studies would indicate
that, for the mouse bladder, a dose of 5 to 10 mg kg-1
Photofrin, given 1 to 7 days before whole bladder illumina-
tion with an incident, non scattered light dose of 11.3 J cm-2
achieves this aim. The total fluence, including scattered light,
in a closed system like the bladder is always much greater
than the incident light dose (Star et al., 1987) but can only be
determined accurately if the optical properties of the tissue in
question are known. Previous calculations (see discussion of
Stewart et al., 1992) indicate that the total fluence in these
mouse bladders is three to four times the incident light dose.
The bladder is able to recover completely from PDT using
such schedules. However, care should be taken to avoid
bacterial infection during the acute reaction period, since
ascending urinary tract infection may well be associated with
permanent renal damage.
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